Literature DB >> 25781902

Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.

Yugo Sawada1, Kazuya Omoto1, Naoki Kohei1, Kengo Sakaguchi2, Masahiko Miura3, Kazunari Tanabe1.   

Abstract

OBJECTIVES: To examine the effects of combined treatment with sulfoquinovosylacylpropanediol and X-ray irradiation on the remodeling of the prostate cancer microenvironment, including angiogenic and hypoxic characteristics.
METHODS: Human prostate cancer cells (DU145 and PC3) were implanted subcutaneously into the right hind legs of athymic nude mice. After the tumor volume reached 100-300mm(3) , 2mg/kg/day sulfoquinovosylacylpropanediol was given intravenously from day0 to day4, and cells were exposed to 4Gy X-ray irradiation on days0 and 3 (for a total of 8Gy). Tumors were fixed and stained for pathological analyses and immunohistochemical evaluations. To analyze vascular normalization, 60mg/kg pimonidazole dissolved in saline was injected intraperitoneally.
RESULTS: Combined treatment with sulfoquinovosylacylpropanediol plus X-ray irradiation enhanced growth inhibition in DU145 xenografts. The tumor vessel density in DU145 cells significantly decreased after the combined treatment. Staining for αsmooth muscle actin in vessels was significantly increased. Pimonidazole staining, showing hypoxic lesions, was negative from 72h, but positive at 6 and 24h after the first combined treatment. In contrast, no enhancement of the microenvironment in PC3 xenografts was observed with sulfoquinovosylacylpropanediol plus X-ray irradiation.
CONCLUSION: Sulfoquinovosylacylpropanediol could be a novel potent radiosensitizing agent targeting angiogenesis in prostate cancer.
© 2015 The Japanese Urological Association.

Entities:  

Keywords:  oxygenation; prostate cancer; radiation therapy; radiosensitizer; vascular normalization

Mesh:

Substances:

Year:  2015        PMID: 25781902     DOI: 10.1111/iju.12753

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  4 in total

1.  A Multimodal Molecular Imaging Study Evaluates Pharmacological Alteration of the Tumor Microenvironment to Improve Radiation Response.

Authors:  Yoichi Takakusagi; Sarwat Naz; Kaori Takakusagi; Masahiro Ishima; Hiroshi Murata; Keisuke Ohta; Masahiko Miura; Fumio Sugawara; Kengo Sakaguchi; Shun Kishimoto; Jeeva P Munasinghe; James B Mitchell; Murali C Krishna
Journal:  Cancer Res       Date:  2018-10-09       Impact factor: 12.701

2.  Anticancer agent α-sulfoquinovosyl-acylpropanediol enhances the radiosensitivity of human malignant mesothelioma in nude mouse models.

Authors:  Eiko Inamasu; Tomoshi Tsuchiya; Motohiro Yamauchi; Kodai Nishi; Katsuya Matsuda; Fumio Sugawara; Kengo Sakaguchi; Ryoichi Mori; Keitaro Matsumoto; Takuro Miyazaki; Go Hatachi; Ryoichiro Doi; Hironosuke Watanabe; Koichi Tomoshige; Naoki Matsuda; Yoshikazu Higami; Isao Shimokawa; Masahiro Nakashima; Takeshi Nagayasu
Journal:  J Radiat Res       Date:  2022-01-20       Impact factor: 2.724

3.  The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3.

Authors:  Yoichi Takakusagi; Aya Sugyo; Atsushi B Tsuji; Hitomi Sudo; Masahiro Yasunaga; Yasuhiro Matsumura; Fumio Sugawara; Kengo Sakaguchi; Tatsuya Higashi
Journal:  Transl Oncol       Date:  2021-11-25       Impact factor: 4.243

4.  Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulates its activity.

Authors:  Jesus Izaguirre-Carbonell; Hirofumi Kawakubo; Hiroshi Murata; Atsushi Tanabe; Toshifumi Takeuchi; Tomoe Kusayanagi; Senko Tsukuda; Takeshi Hirakawa; Kazuki Iwabata; Yoshihiro Kanai; Keisuke Ohta; Masahiko Miura; Kengo Sakaguchi; Sachihiro Matsunaga; Hiroeki Sahara; Shinji Kamisuki; Fumio Sugawara
Journal:  Sci Rep       Date:  2015-10-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.